With New GPCR Patent in Hand, Odyssey Thera Looks at High-Content Receptor Signaling

The patent, called “Fragment Complementation Assays for G Protein-Coupled Receptors and Their Signaling Pathways,” solidifies Odyssey’s position in complex-based assays, and adds depth to its IP coverage in these two areas, an Odyssey official told CBA News this week.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories